Monday, November 20, 2023

MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Scientific Advisory Board as It Advances Product Development, Clinical and Commercial Efforts

 HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, today announced the expansion of its scientific advisory board (“SAB”) to include several leading cardiologists. New members include Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise, Tony Das, MD, a nationally recognized board-certified interventional cardiology specialist, leader and educator in the field of cardiovascular diseases, Robert Harrington, MD, dean of Weill Cornell Medicine and provost for medical affairs of Cornell University, Campbell Rogers, MD, EVP and chief medical officer at HeartFlow Inc., and Niraj Varma, MD, Ph.D., professor of medicine and consultant electrophysiologist at the Cleveland Clinic. “We are honored and pleased to have such a distinguished group of physicians joining our scientific advisory board,” said Branislav Vajdic, Ph.D., CEO and founder of HeartBeam. “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies. We look forward to working closely with all the SAB members as we advance our product development, clinical and commercial efforts.”

To view the full press release, visit https://ibn.fm/JrOH0

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN